Liprolog Basal KwikPen: Uses, Dosage & Side Effects
An intermediate-acting insulin analog (insulin lispro protamine) in a disposable pre-filled pen for blood glucose control in diabetes mellitus
Liprolog Basal KwikPen contains insulin lispro protamine, an intermediate-acting insulin analog used to manage blood glucose levels in patients with diabetes mellitus (both type 1 and type 2). The protamine suspension delays absorption from the injection site, providing a prolonged duration of action of up to 24 hours with peak activity occurring between 4 and 12 hours after injection. Administered subcutaneously once or twice daily using a convenient disposable pre-filled pen, Liprolog Basal KwikPen is typically used as part of a basal-bolus insulin regimen alongside a rapid-acting insulin at mealtimes, or in combination with oral antidiabetic agents for type 2 diabetes. The pen design simplifies dose selection and injection technique, supporting improved adherence and glycemic control.
Quick Facts: Liprolog Basal KwikPen
Key Takeaways
- Liprolog Basal KwikPen contains insulin lispro protamine, an intermediate-acting insulin analog that provides background (basal) blood glucose control for up to 24 hours, with peak action at 4–12 hours after injection.
- It is indicated for adults and children with type 1 or type 2 diabetes mellitus who require insulin therapy, and is usually combined with a rapid-acting insulin for mealtime coverage or with oral antidiabetic medications.
- The most common side effect is hypoglycemia (low blood sugar), which can be prevented through careful dose titration, regular blood glucose monitoring, consistent meal schedules, and appropriate carbohydrate intake.
- The pre-filled KwikPen device allows convenient and accurate dose selection from 1 to 60 units per injection, and the suspension must be gently resuspended before each use by rolling the pen between the palms.
- Unopened pens should be refrigerated at 2–8 °C; once in use, they may be kept at room temperature (below 30 °C) for up to 28 days, after which any remaining insulin must be discarded.
What Is Liprolog Basal KwikPen and What Is It Used For?
Liprolog Basal KwikPen contains the active substance insulin lispro protamine, which belongs to the pharmacological class of intermediate-acting insulin analogs (ATC code A10AC04). Insulin lispro protamine is produced by complexing the rapid-acting insulin analog insulin lispro with protamine sulfate, a positively charged protein derived from fish sperm. This complexation creates a crystalline suspension that, when injected subcutaneously, dissolves slowly at the injection site, thereby delaying the absorption of insulin lispro into the bloodstream and extending its duration of action significantly compared to the unmodified rapid-acting form.
The pharmacokinetic profile of insulin lispro protamine is similar to that of neutral protamine Hagedorn (NPH) insulin, the established intermediate-acting human insulin preparation that has been a cornerstone of diabetes treatment for decades. After subcutaneous injection, insulin lispro protamine has an onset of action of approximately 1 to 2 hours, reaches peak plasma concentrations and maximal glucose-lowering effect between 4 and 12 hours post-injection, and maintains a clinically meaningful duration of action for up to 24 hours. This time-action profile makes it well-suited for providing basal insulin coverage—the continuous, background level of insulin needed to regulate hepatic glucose output and maintain stable blood glucose levels between meals and during sleep.
Insulin, produced naturally by the beta cells of the pancreatic islets of Langerhans, is the body’s primary anabolic hormone. It exerts its effects by binding to the insulin receptor, a transmembrane tyrosine kinase receptor expressed on the surface of target cells in skeletal muscle, adipose tissue, and the liver. Upon receptor activation, insulin triggers a complex intracellular signaling cascade that promotes glucose uptake into skeletal muscle and fat cells via translocation of GLUT4 glucose transporters to the cell surface, stimulates glycogen synthesis in the liver and muscle, inhibits hepatic gluconeogenesis and glycogenolysis, promotes lipogenesis and inhibits lipolysis in adipose tissue, and facilitates amino acid uptake and protein synthesis. In diabetes mellitus, the body either cannot produce sufficient insulin (type 1 diabetes, caused by autoimmune destruction of beta cells) or cannot use it effectively due to insulin resistance (type 2 diabetes), leading to chronic hyperglycemia and its associated micro- and macrovascular complications.
Liprolog Basal KwikPen is indicated for the treatment of diabetes mellitus in adults and children who require insulin for the maintenance of normal glucose homeostasis. In clinical practice, it is used in the following therapeutic contexts:
- Type 1 diabetes mellitus: As part of a basal-bolus insulin regimen, where Liprolog Basal provides the basal component (typically injected once or twice daily) and a rapid-acting insulin (such as regular Liprolog/insulin lispro) is administered before meals to cover postprandial glucose excursions. This regimen closely mimics the physiological pattern of endogenous insulin secretion and is recommended by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as the standard of care for type 1 diabetes.
- Type 2 diabetes mellitus: As a basal insulin supplement to oral antidiabetic medications (such as metformin, sulfonylureas, or SGLT2 inhibitors) when these agents alone are insufficient to achieve glycemic targets. It may also be used as part of a full basal-bolus regimen in patients with more advanced type 2 diabetes who have significant beta-cell dysfunction. International guidelines from the ADA and EASD recommend initiating basal insulin when HbA1c remains above target (typically >7.0% or individualized) despite maximized oral therapy.
The KwikPen device is a disposable, pre-filled insulin delivery system manufactured by Eli Lilly. It contains 3 mL of insulin lispro protamine suspension at a concentration of 100 units per milliliter (U-100), providing a total of 300 units per pen. The pen allows dose selection in increments of 1 unit, with a maximum single injection dose of 60 units. The integrated dose dial, push-button injection mechanism, and clear dose window make it straightforward for patients of all ages to use, contributing to improved adherence and accuracy of insulin delivery. Compatible pen needles (not included with the pen) must be attached before each injection and discarded safely after use.
Basal-bolus therapy is the gold standard for intensive insulin management. The “basal” component (provided by Liprolog Basal KwikPen) delivers a steady background level of insulin throughout the day and night, mimicking the low-level continuous insulin secretion of a healthy pancreas. The “bolus” component (a rapid-acting insulin like Liprolog/insulin lispro) is given before meals to handle the glucose spike from food intake. Together, these two components aim to reproduce normal physiological insulin patterns as closely as possible, optimizing blood glucose control while minimizing the risk of hypoglycemia.
What Should You Know Before Taking Liprolog Basal KwikPen?
Contraindications
Liprolog Basal KwikPen must not be used in the following situations:
- Hypoglycemia: The most fundamental contraindication to insulin administration is active hypoglycemia (low blood sugar). Administering insulin when blood glucose is already low can precipitate severe hypoglycemia, potentially leading to loss of consciousness, seizures, brain injury, or death. Always check blood glucose levels before injecting insulin if there is any doubt about your current glycemic status.
- Hypersensitivity: Do not use Liprolog Basal KwikPen if you have a known allergy to insulin lispro or to any of the excipients in the formulation, including protamine sulfate, m-cresol (preservative), glycerol, dibasic sodium phosphate heptahydrate, zinc oxide, phenol, and water for injection. Allergic reactions can range from localized injection site reactions to systemic anaphylaxis.
- Intravenous administration: Liprolog Basal KwikPen is a suspension formulation designed exclusively for subcutaneous injection. It must never be administered intravenously, as this could result in severe hypoglycemia and potentially dangerous embolic complications from the particulate suspension. It must also not be used in insulin infusion pumps.
Warnings and Precautions
Hypoglycemia is the most common and potentially serious adverse effect of insulin therapy. Symptoms include sweating, trembling, rapid heartbeat, hunger, dizziness, blurred vision, confusion, and difficulty concentrating. Severe hypoglycemia can cause loss of consciousness, seizures, and can be life-threatening. Always carry a fast-acting source of glucose (such as glucose tablets, juice, or sweets) and ensure that family members, caregivers, and colleagues know how to recognize and treat hypoglycemia.
Before starting treatment with Liprolog Basal KwikPen, discuss the following with your healthcare provider:
- Dose adjustment needs: Your insulin dose may need to be adjusted when changing from another type of insulin, when your diet or exercise patterns change, during illness or emotional stress, when traveling across time zones, or if you start or stop other medications that affect blood glucose. Never adjust your insulin dose without consulting your doctor.
- Liver or kidney disease: Impaired liver or kidney function can affect insulin metabolism and clearance, potentially increasing the risk and duration of hypoglycemia. Your doctor may need to reduce your insulin dose and increase the frequency of blood glucose monitoring if you have hepatic or renal impairment.
- Hypoglycemia unawareness: Some patients, particularly those with long-standing diabetes or those taking beta-blockers, may lose the ability to recognize the early warning symptoms of hypoglycemia (hypoglycemia unawareness). These patients are at significantly increased risk of severe hypoglycemic episodes. If you have experienced hypoglycemia without warning symptoms, discuss strategies with your doctor such as relaxing glycemic targets and intensifying blood glucose monitoring.
- Diabetic ketoacidosis (DKA): If you have type 1 diabetes, never stop taking your insulin, even if you are unwell and unable to eat normally. Omission of insulin in type 1 diabetes can rapidly lead to diabetic ketoacidosis, a life-threatening emergency characterized by very high blood glucose, ketone accumulation in the blood, metabolic acidosis, dehydration, and altered consciousness. Seek emergency medical care if you develop symptoms of DKA, including nausea, vomiting, abdominal pain, fruity-smelling breath, or deep rapid breathing.
- Injection site rotation: Failure to rotate injection sites can lead to lipodystrophy (localized changes in subcutaneous fat tissue), including lipohypertrophy (thickening) or lipoatrophy (thinning). These tissue changes can impair insulin absorption and lead to erratic blood glucose levels. Always rotate injection sites within the same general anatomical area.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using or continuing Liprolog Basal KwikPen. Maintaining excellent blood glucose control during pregnancy is essential for the health of both the mother and the developing baby. Poorly controlled diabetes during pregnancy is associated with increased risks of congenital malformations, macrosomia (excessively large baby), preeclampsia, and neonatal complications including hypoglycemia and respiratory distress syndrome.
Insulin requirements typically decrease during the first trimester of pregnancy and increase substantially during the second and third trimesters. After delivery, insulin requirements usually return rapidly to pre-pregnancy levels. Close monitoring and frequent dose adjustments under the supervision of an experienced diabetes care team are essential throughout pregnancy and the postpartum period.
Insulin lispro protamine can be used during breastfeeding. Insulin is a naturally occurring protein that is degraded in the infant’s gastrointestinal tract and is not absorbed systemically from breast milk. Therefore, it poses no risk to the breastfed infant. However, your insulin dose and dietary needs may need adjustment during the breastfeeding period, and regular blood glucose monitoring is recommended.
Children and Adolescents
Liprolog Basal KwikPen can be used in children and adolescents who require intermediate-acting insulin therapy. Dosing in pediatric patients is based on the same principles as in adults, with individualized dose titration guided by blood glucose monitoring. Children and adolescents may have different insulin sensitivity and activity patterns compared to adults, and their insulin requirements may change significantly during growth spurts and puberty. Close collaboration between the child, parents or caregivers, and the pediatric diabetes care team is essential for safe and effective insulin management.
How Does Liprolog Basal KwikPen Interact with Other Drugs?
Insulin does not undergo hepatic metabolism via cytochrome P450 enzymes, and therefore does not have classical pharmacokinetic drug-drug interactions. However, many medications have pharmacodynamic effects on glucose metabolism that can significantly alter insulin requirements. Understanding these interactions is crucial for maintaining safe and effective blood glucose control. Your healthcare provider should review all your medications regularly and adjust your insulin dose accordingly.
Medications That May Increase Hypoglycemic Effect
The following medications can lower blood glucose levels or enhance insulin sensitivity, potentially increasing the risk of hypoglycemia when used alongside Liprolog Basal KwikPen. Dose reduction of insulin and more frequent blood glucose monitoring may be necessary:
| Drug Class | Examples | Mechanism |
|---|---|---|
| Oral antidiabetic agents | Metformin, sulfonylureas (glimepiride, gliclazide), SGLT2 inhibitors (dapagliflozin, empagliflozin) | Additive glucose-lowering effect via complementary mechanisms |
| ACE inhibitors | Enalapril, lisinopril, ramipril | May improve insulin sensitivity and reduce insulin resistance |
| MAO inhibitors | Moclobemide, phenelzine | Enhance insulin secretion and may reduce hepatic glucose output |
| Beta-blockers | Propranolol, atenolol, metoprolol | May mask symptoms of hypoglycemia (especially tachycardia and tremor) and prolong hypoglycemic episodes |
| Salicylates | Aspirin (high dose) | Enhance peripheral glucose utilization at high doses |
| Fibrates | Fenofibrate, gemfibrozil | May improve insulin sensitivity |
| Alcohol | Ethanol | Inhibits hepatic gluconeogenesis, increasing the risk of delayed hypoglycemia |
Medications That May Reduce Hypoglycemic Effect
The following medications can raise blood glucose levels or reduce insulin sensitivity, potentially leading to hyperglycemia. An increase in insulin dose may be required when starting these medications:
| Drug Class | Examples | Mechanism |
|---|---|---|
| Corticosteroids | Prednisolone, dexamethasone, hydrocortisone | Stimulate hepatic gluconeogenesis and induce insulin resistance |
| Thiazide diuretics | Hydrochlorothiazide, bendroflumethiazide | Impair insulin secretion and reduce peripheral glucose utilization |
| Thyroid hormones | Levothyroxine | Increase hepatic glucose production and intestinal glucose absorption |
| Sympathomimetics | Salbutamol, terbutaline, adrenaline | Stimulate glycogenolysis and gluconeogenesis via beta-adrenergic activation |
| Growth hormone | Somatotropin | Induces insulin resistance and increases hepatic glucose output |
| Oral contraceptives | Combined oral contraceptive pills | May modestly reduce insulin sensitivity |
| Atypical antipsychotics | Olanzapine, clozapine, quetiapine | Induce weight gain and metabolic disturbances including insulin resistance |
Beta-blockers deserve special attention because they have a dual effect: they may slightly enhance insulin’s glucose-lowering action, but more importantly, they can mask the characteristic warning symptoms of hypoglycemia, particularly tachycardia (rapid heart rate) and tremor. Patients taking beta-blockers along with insulin should be educated about alternative hypoglycemia symptoms (such as sweating, hunger, and cognitive changes) and may need to monitor blood glucose more frequently.
In addition to the drug categories listed above, changes in dietary habits, physical activity levels, illness, and emotional stress can all significantly affect insulin requirements. Patients should be counseled to monitor blood glucose closely during any such changes and to contact their healthcare provider for guidance on dose adjustment. The use of alcohol requires particular caution, as even moderate alcohol consumption can inhibit hepatic gluconeogenesis and substantially increase the risk of delayed hypoglycemia, particularly during the overnight period.
What Is the Correct Dosage of Liprolog Basal KwikPen?
Insulin dosing is one of the most individualized aspects of diabetes pharmacotherapy. Unlike most medications with fixed dosing regimens, the appropriate dose of Liprolog Basal KwikPen varies widely between patients and can change over time in the same patient based on numerous factors. The overarching goal of insulin dosing is to achieve and maintain blood glucose levels as close to the normal physiological range as possible (typically HbA1c <7.0% for most adults, or individualized targets), while minimizing the risk of hypoglycemia and excessive weight gain.
Adults
For adult patients with diabetes, the starting dose and subsequent titration of Liprolog Basal KwikPen are determined by the treating physician based on multiple factors including the type of diabetes, current blood glucose levels and HbA1c, body weight, previous insulin therapy history, concurrent medications, dietary patterns, and physical activity level. The following table provides general dosing guidelines:
| Patient Group | Typical Starting Dose | Frequency | Titration Guidance |
|---|---|---|---|
| Type 1 Diabetes (Basal-Bolus) | 40–50% of total daily insulin dose as basal | Once or twice daily | Adjust by 1–2 units every 3–7 days based on fasting glucose |
| Type 2 Diabetes (Basal + Oral Agents) | 10 units or 0.1–0.2 U/kg once daily | Once daily (usually at bedtime) | Increase by 2–4 units every 3–7 days until fasting glucose target is reached |
| Type 2 Diabetes (Basal-Bolus) | 40–50% of total daily insulin dose as basal | Once or twice daily | Adjust by 1–2 units every 3–7 days based on fasting glucose |
When Liprolog Basal KwikPen is administered once daily, it is typically injected in the evening (at bedtime) or at the same time each day. When twice-daily dosing is required, the total basal dose is usually split between a morning injection and an evening injection. Consistency in the timing of injections is important for maintaining stable blood glucose control. The pen allows dose selection in 1-unit increments up to a maximum of 60 units per injection.
Children and Adolescents
Dosing in pediatric patients follows the same general principles as in adults. The total daily insulin requirement in children and adolescents with type 1 diabetes is typically 0.5 to 1.0 units per kilogram of body weight per day, with approximately 40–50% given as basal insulin and the remainder as rapid-acting insulin at mealtimes. During puberty, insulin requirements often increase substantially (sometimes exceeding 1.5 U/kg/day) due to increased levels of growth hormone and sex steroids, which induce physiological insulin resistance. Frequent dose adjustments are essential during periods of growth. The pediatric diabetes care team should guide all dosing decisions.
Elderly Patients
Elderly patients may have altered insulin sensitivity and renal function, both of which can affect insulin clearance and the risk of hypoglycemia. The ADA recommends less stringent glycemic targets for older adults (HbA1c <8.0% or individualized) to reduce the risk of severe hypoglycemia, which can have particularly devastating consequences in the elderly, including falls, fractures, cardiovascular events, and cognitive decline. Conservative initial dosing and gradual titration are advised, with regular monitoring and proactive adjustment of doses to balance glucose control with safety.
Missed Dose
If you miss a scheduled dose of Liprolog Basal KwikPen, take it as soon as you remember, provided it is not close to the time of your next scheduled dose. Do not inject a double dose to compensate for a missed one. If you are uncertain about how to proceed after missing a dose, check your blood glucose level and contact your healthcare provider or diabetes nurse for advice. Missing one or two doses of basal insulin in type 1 diabetes can lead to rapid development of hyperglycemia and potentially diabetic ketoacidosis, so prompt action is essential.
Overdose
Insulin overdose can cause hypoglycemia, which ranges in severity from mild (easily treated with oral carbohydrates) to severe (requiring assistance from another person, and potentially causing loss of consciousness, seizures, or death). Treatment of insulin overdose depends on the severity:
- Mild to moderate hypoglycemia: Treat by ingesting fast-acting carbohydrates such as glucose tablets (15–20 grams), fruit juice, regular soft drinks, or sweets. Recheck blood glucose after 15 minutes and repeat treatment if blood glucose remains below 4 mmol/L (72 mg/dL). Follow with a snack or meal containing complex carbohydrates to prevent recurrence.
- Severe hypoglycemia: If the person is unconscious or unable to swallow safely, do not attempt to give food or drink by mouth. Administer glucagon injection (if available and if a trained caregiver is present) and call emergency services immediately. Intravenous glucose (dextrose) may be required in the hospital setting. After recovery from severe hypoglycemia, the patient should be monitored closely for several hours, as intermediate-acting insulins can cause prolonged or recurrent hypoglycemia.
Severe hypoglycemia is a medical emergency. If a person with diabetes becomes unconscious or is having seizures, place them in the recovery position, do not give anything by mouth, administer glucagon if available, and call emergency services immediately. Do not attempt to inject insulin. After recovery, report the episode to the patient’s diabetes care team for review and dose adjustment.
What Are the Side Effects of Liprolog Basal KwikPen?
Like all insulin preparations, Liprolog Basal KwikPen can cause side effects, although not everybody gets them. The most frequently observed adverse effect across all insulin therapies is hypoglycemia, which is a direct consequence of the drug’s pharmacological action. The risk of hypoglycemia depends on the insulin dose relative to the patient’s caloric intake and energy expenditure, and can be influenced by many factors including meal timing, exercise, alcohol consumption, and concurrent medications.
The following side effects have been reported with insulin lispro protamine and insulin preparations in general, classified by frequency according to the standard conventions used in the European Summary of Product Characteristics (SmPC):
Very Common
Affects more than 1 in 10 patients
- Hypoglycemia (low blood sugar) — symptoms include sweating, trembling, rapid heartbeat, hunger, dizziness, blurred vision, tingling, confusion, difficulty concentrating, and weakness
Common
Affects 1 in 10 to 1 in 100 patients
- Injection site reactions — redness (erythema), pain, itching, swelling, or hardening at the injection site
- Lipodystrophy at injection sites — lipohypertrophy (thickened fatty lumps) or lipoatrophy (loss of subcutaneous fat)
- Localized allergic reactions — redness, swelling, or itching at the injection site that resolves within a few days to weeks
- Weight gain — a recognized effect of insulin therapy related to the anabolic effects of insulin and reduced glycosuria
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Generalized allergic reactions — urticaria (hives), angioedema, generalized pruritus
- Peripheral edema — fluid retention, particularly at the initiation of insulin therapy or after rapid improvement in glycemic control
- Visual disturbances — transient changes in vision, particularly blurring, may occur at the start of insulin treatment due to changes in lens refraction caused by altered blood glucose levels; these are usually temporary
Rare
Affects fewer than 1 in 1,000 patients
- Anaphylaxis — severe systemic allergic reaction with potential for circulatory collapse; requires immediate emergency treatment with epinephrine (adrenaline)
- Peripheral neuropathy — painful neuropathy has been rarely reported upon rapid improvement in glycemic control (“treatment-induced neuropathy”), which is usually transient
Not Known
Frequency cannot be estimated from available data
- Insulin antibody formation — development of antibodies to insulin lispro; rarely clinically significant, but in exceptional cases may necessitate dose adjustment
- Hypokalemia — insulin can shift potassium from the extracellular to the intracellular compartment, potentially causing low serum potassium levels, which may be clinically relevant in patients receiving potassium-lowering agents or those with pre-existing hypokalemia
If you experience any side effects, including any not listed here, talk to your doctor, pharmacist, or diabetes nurse. You can also report side effects directly through your national adverse drug reaction reporting system, such as the Yellow Card Scheme in the United Kingdom, MedWatch in the United States, or EudraVigilance in the European Union. By reporting side effects, you help provide more information on the safety of this medicine.
Lipodystrophy (fatty lumps or dents at injection sites) is a common but preventable complication of insulin therapy. It occurs when insulin is repeatedly injected into the same spot. Injecting into lipodystrophic areas can cause unpredictable insulin absorption, leading to erratic blood glucose levels. To prevent lipodystrophy, always rotate your injection sites systematically within the same general anatomical region (e.g., different areas within the abdomen), use a new needle for each injection, and check your injection sites regularly for any lumps or dents. If lipodystrophy has developed, avoid injecting into the affected area and consult your diabetes care team.
How Should You Store Liprolog Basal KwikPen?
Proper storage of insulin is essential for maintaining its potency and ensuring safe and effective treatment. Insulin that has been exposed to extreme temperatures, frozen, or kept beyond its recommended use-by period may lose its effectiveness or become unsafe to use. Always check the appearance of the insulin suspension before each injection.
Before Opening (Unopened Pens)
- Store in a refrigerator at 2 to 8 °C (36 to 46 °F).
- Do not freeze. If the insulin has been frozen, it must be discarded—freezing destroys the insulin protein structure and renders it ineffective.
- Keep the pen in the outer carton to protect from light.
- Do not use after the expiry date printed on the label and carton.
- Do not store next to the freezer compartment or cooling element of the refrigerator.
After Opening (In-Use Pens)
- Store at room temperature, below 30 °C (86 °F), away from direct heat and sunlight.
- Do not refrigerate an in-use pen. Cold insulin can be uncomfortable to inject and may affect absorption.
- The in-use pen must be discarded after 28 days, regardless of whether insulin remains in the pen.
- Keep the pen cap on when not in use to protect from light.
- Remove and safely dispose of the pen needle after each injection. Do not store the pen with a needle attached, as this can allow air to enter the cartridge, contaminate the insulin, or cause leakage.
Appearance Before Use
Liprolog Basal KwikPen is a suspension, which means the insulin particles settle to the bottom of the cartridge when the pen is not in use. Before each injection, the pen must be gently rolled between the palms at least 10 times and inverted (turned upside down) at least 10 times to resuspend the insulin uniformly. After resuspension, the insulin should appear uniformly cloudy or milky white. Do not use the pen if the resuspended insulin remains clear, contains solid particles or clumps, has a frosted appearance on the cartridge wall, or appears discolored. These changes may indicate that the insulin has degraded and is no longer effective.
When traveling, keep your Liprolog Basal KwikPen in a cool bag or insulated case to protect it from extreme temperatures. Insulin should never be placed in checked luggage on an airplane (cargo holds can reach freezing temperatures). Carry your insulin in your hand luggage, ideally with a cooling wallet if traveling to hot climates. When crossing time zones, consult your diabetes care team about adjusting your injection schedule. Always carry at least twice as much insulin and supplies as you expect to need, in case of travel delays or losses.
What Does Liprolog Basal KwikPen Contain?
Understanding the composition of your insulin preparation is important, particularly if you have known allergies to any pharmaceutical excipients. The full composition of Liprolog Basal KwikPen is as follows:
Active Substance
Each milliliter contains 100 units (equivalent to approximately 3.5 mg) of insulin lispro protamine. Insulin lispro is a recombinant human insulin analog produced in Escherichia coli using recombinant DNA technology. It differs from human insulin by a reversal of the amino acids at positions 28 (proline to lysine) and 29 (lysine to proline) of the B chain. The complexation with protamine sulfate creates the intermediate-acting suspension that provides prolonged glucose-lowering activity.
Excipients (Inactive Ingredients)
- Protamine sulfate: A basic protein that complexes with insulin lispro to delay its absorption; derived from fish (salmon) sperm. Patients with known fish allergy should discuss this with their doctor, although cross-reactivity is considered extremely rare.
- m-Cresol: An antimicrobial preservative that maintains sterility of the multi-dose preparation during the 28-day in-use period.
- Glycerol (glycerin): An isotonicity agent that adjusts the osmolarity of the solution to match body fluids, reducing injection site pain.
- Dibasic sodium phosphate heptahydrate: A buffer that maintains the pH of the suspension within the optimal range for stability and comfort.
- Zinc oxide: Provides zinc ions that contribute to the stability of the insulin-protamine crystal complex.
- Phenol: An additional antimicrobial preservative.
- Water for injection: The solvent base of the suspension.
Hydrochloric acid and/or sodium hydroxide may have been used during manufacturing to adjust the pH. The product contains less than 1 mmol (23 mg) sodium per dose, meaning it is essentially sodium-free.
Pen Device Details
Each Liprolog Basal KwikPen contains 3 mL of suspension, providing a total of 300 units of insulin lispro protamine. The pen is a disposable, single-patient-use device with a built-in dose selector that allows dosing from 1 to 60 units per injection in 1-unit increments. The pen requires compatible insulin pen needles (typically 4 mm, 5 mm, or 8 mm in length), which are attached before each injection and discarded safely afterward. The pen body is made of medical-grade polypropylene and polycarbonate, with an internal glass cartridge sealed with a rubber stopper and aluminum crimp cap.
Frequently Asked Questions About Liprolog Basal KwikPen
Regular Liprolog contains insulin lispro, a rapid-acting insulin analog that starts working within 15 minutes of injection and lasts for 2–5 hours. It is used before meals to control blood sugar spikes from food. Liprolog Basal contains insulin lispro protamine, where the insulin lispro is combined with protamine to slow its absorption. This gives it an intermediate duration of action (up to 24 hours), making it suitable for providing background insulin throughout the day and night. Many patients use both products as part of a basal-bolus regimen: Liprolog Basal for background coverage and regular Liprolog for mealtime coverage.
No, you should not mix any other insulin or medication in the Liprolog Basal KwikPen. The pen is a pre-filled device containing a specific insulin formulation, and adding other substances could alter the pharmacokinetics, sterility, or stability of the product. If your doctor prescribes both a basal and a rapid-acting insulin, they should be administered as separate injections at different sites or at different times. Some patients may be prescribed a pre-mixed insulin formulation (such as Liprolog Mix) that contains both rapid-acting and intermediate-acting insulin in a single pen, but this is a different product and should not be confused with Liprolog Basal.
Before each injection, gently resuspend the insulin by rolling and inverting the pen. The properly resuspended insulin should look uniformly cloudy or milky white. Do not use the insulin if it remains clear after resuspension (this would indicate that the protamine-insulin crystals have not formed properly), if you can see clumps, flakes, or solid particles that do not disappear after gentle mixing, if there is a frosted appearance on the inside of the cartridge wall, or if the insulin appears discolored. Also discard the pen if it has been frozen, if it has been in use for more than 28 days, if the expiry date has passed, or if it has been stored above 30 °C for extended periods.
If you inject too much Liprolog Basal KwikPen, your blood sugar may drop too low (hypoglycemia). For mild hypoglycemia (you are conscious and able to swallow), immediately consume 15–20 grams of fast-acting carbohydrates such as glucose tablets, fruit juice, or regular soft drinks. Wait 15 minutes and recheck your blood glucose. If it remains low, repeat the treatment. Once your blood sugar has normalized, eat a snack or meal containing complex carbohydrates to prevent recurrence. Because Liprolog Basal is an intermediate-acting insulin, the hypoglycemic effect can persist for many hours, so continued monitoring is essential. If you experience severe hypoglycemia (loss of consciousness, seizures, inability to swallow), this is a medical emergency—someone should administer glucagon and call emergency services immediately.
Yes, insulin lispro protamine can be used during pregnancy under medical supervision. Good blood glucose control before and during pregnancy is essential for the health of both mother and baby. Insulin is the preferred treatment for diabetes during pregnancy because it does not cross the placenta in clinically significant amounts. However, insulin requirements change significantly throughout pregnancy: they typically decrease in the first trimester and increase in the second and third trimesters. Close collaboration with your diabetes care team, including frequent blood glucose monitoring and dose adjustments, is essential throughout pregnancy and the postpartum period.
Liprolog Basal KwikPen (insulin lispro protamine) is classified as an intermediate-acting insulin, while insulin glargine (Lantus, Toujeo) and insulin degludec (Tresiba) are long-acting basal insulins. The key differences are in their pharmacokinetic profiles: intermediate-acting insulins have a more pronounced peak of action (4–12 hours) and somewhat shorter duration, while long-acting insulins provide a relatively flat, peakless profile over 24 hours or longer. Long-acting insulins are generally associated with a lower risk of nocturnal hypoglycemia and more consistent day-to-day glucose levels. However, intermediate-acting insulins remain widely used and effective, particularly in resource-constrained settings or when a specific peak of action is clinically desired. Your doctor will choose the most appropriate basal insulin based on your individual needs, lifestyle, and treatment goals.
References
This article is based on evidence from the following peer-reviewed and authoritative sources:
- European Medicines Agency (EMA). Liprolog Basal – Summary of Product Characteristics. European Medicines Agency, 2025. Available at: www.ema.europa.eu.
- American Diabetes Association (ADA). Standards of Care in Diabetes—2026. Diabetes Care, 2026; 49(Suppl 1): S1–S291. doi: 10.2337/dc26-Sint.
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022; 45(11): 2753–2786. doi: 10.2337/dci22-0034.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. World Health Organization, Geneva, 2023.
- National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management (NG17). Updated 2024. Available at: www.nice.org.uk/guidance/ng17.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024. Available at: www.nice.org.uk/guidance/ng28.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition, 2021. International Diabetes Federation, Brussels.
- Frid AH, Kreugel G, Grassi G, et al. New Insulin Delivery Recommendations. Mayo Clin Proc, 2016; 91(9): 1231–1255. doi: 10.1016/j.mayocp.2016.06.010.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, diabetology, and clinical pharmacology.
Medical Content
Written by physicians with specialist training in endocrinology and diabetes management, with expertise in insulin pharmacology and diabetes education.
Medical Review
Independently reviewed by the iMedic Medical Review Board according to international guidelines from the ADA, EASD, WHO, and EMA.
Evidence Standards
All clinical claims are supported by Level 1A evidence from systematic reviews, meta-analyses, and international clinical guidelines. GRADE evidence framework applied.
Editorial Independence
No pharmaceutical industry funding, sponsorship, or advertising. All content is editorially independent with full conflict-of-interest disclosure.